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Abstract 
Background: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis impact significantly on health-related quality of life (HRQOL). There are few 
studies on the impact of confidence on HRQOL in these conditions. 
Objectives:  1. To investigate whether patient confidence is associated with   HRQOL. 
2. To assess if patient confidence is associated with inpatient admissions, access to community healthcare and, for IPF patients, 
mortality and disease  severity. 
Methods: Study participants self-completed seven questionnaires: Hospital Anxiety and Depression Scale, EuroQol 5D (EQ5D) , King’s Brief 
Interstitial Lung Disease questionnaire (K- BILD), St George’s Respiratory Questionnaire, MRC dyspnoea scale, Fatigue Assessment    Scale and 
a non-validated questionnaire assessing patient confidence, symptom duration   and access to community healthcare. Lung function and 
follow-up data were collected from hospital electronic databases. Spearman’s rank correlation coefficients were calculated to assess for 
correlation between patient confidence, questionnaire variables and inpatient admissions Chi-square tests were performed to assess for 
association between patient confidence, mortality and disease severity. 
Results: 75 IPF patients and 69 sarcoidosis patients were recruited to the study. Patient confidence in IPF was significantly negatively 
correlated   with depression and, fatigue, and significantly positively correlated with EQ5D scores. No associations were found between 
confidence and any of the variables assessed in sarcoidosis. 
Conclusions: Lower levels of confidence in IPF patients are associated with higher levels of depression and fatigue and worse HRQOL. Efforts 
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should be made to improve patient confidence to assess the impact on HRQOL. 
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Introduction 
Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are chronic conditions that have a significant impact on patients’ health-related quality of 
life (HRQOL). In both conditions, this  is affected by factors such as fatigue, mood and sleep quality, which are not always directly linked to 
disease severity (1–3). Impaired health status has a negative impact on patients’ ability to perform activities of daily living (ADLs) and work-
related tasks, as well as their  ability to have normal social interactions (2–5). Increased self-efficacy (which can be defined as the confidence 
people have in managing their health when living with a chronic disease) impacts positively on HRQOL in other conditions such as chronic 
obstructive pulmonary disease (COPD) (6,7), however there are few studies in this area in IPF and sarcoidosis. 
 “Confidence” itself is a non-specific term referring to strength of belief, however it is   an important component of self-efficacy and, as has 
been shown in qualitative studies   of pulmonary rehabilitation in COPD, increased confidence is a positive outcome   of interventions that is 
valued by patients  (8,9). 
 
One study in IPF comparing the PRISM (Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management) programme 
over a six week period with patients receiving their usual level of care (10) found that patients receiving the intervention (PRISM) reported 
worse generic quality of lifehealth status (measured by the Medical   Outcomes 
Study 36-Item Short Form Questionnaire (SF-36)) and anxiety (measured by the Beck Anxiety Inventory) after the programme, although post-
study qualitative   interviews suggested that patients benefitted from the intervention. The IPF Care patient support programme for IPF 
patients receiving pirfenidone has been found to increase patients’ confidence in knowing about the management of their disease and 
feeling in control of their condition (11). Patients in this study most frequently discussed topics that were not directly linked to pirfenidone, 
highlighting the importance of assessing the utility of such   programmes for patients with IPF regardless of whether they are receiving 
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pharmacological treatment. 
In sarcoidosis, although the disease has a negative impact on patients’ quality of life, a lack   of prospective longitudinal follow-up studies 
makes it challenging to draw conclusions about the cause of impaired health status and its consequences (12). Radiographic stage of 
pulmonary sarcoidosis, pulmonary function tests and levels of serum angiotensin converting enzyme (ACE) have been shown to be poorly 
associated with quality of life and levels of fatigue (2,13–15) despite their widespread clinical use as markers of disease   severity. 
Our study aimed to assess the relationship between patient confidence and quality of life, anxiety, depression, dyspnoea and fatigue in 
sarcoidosis and IPF patients. We chose to measure the King’s Brief Interstitial Lung Disease (K-BILD) and St George’s Respiratory 
Questionnaire (SGRQ), designed specifically for patients with lung disease, as well as the EuroQol 5D (EQ5D), a non-disease-specific measure 
of HRQOL, which we   felt  
was a useful tool as sarcoidosis can affect multiple body systems. We also   investigated whether patient confidence was related to access to 
healthcare in the community as well as outcome as measured by emergency hospital admissions. For the IPF cohort, we   assessed the 
relationship of patient confidence with mortality and disease severity as measured by lung function. 
 
Methods 
Patients under the care of the respiratory department at the Norfolk and Norwich University Hospital with a diagnosis of IPF and sarcoidosis 
were identified from an electronic database   of interstitial lung disease (ILD) patients, by their primary consultant physician within clinic,   or 
from patient support days run by the respiratory research group for patients with sarcoidosis or IPF. Participants were eligible for inclusion if 
they were over the age of 18,     had a diagnosis of IPF or sarcoidosis, were able to give informed consent to take part in the study, and did 
not have any major co-morbidities apart from their diagnosed lung   disease. 
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IPF patients were included if they met the diagnostic criteria for IPF as per the American Thoracic Society’s 2011 guidelines (16). Patients in 
the sarcoidosis group required histological evidence of granuloma formation consistent with sarcoidosis plus radiological evidence of 
pulmonary involvement (17).  
 
Patients were recruited to the study between February 2013 and March 2014. This study was conducted in accordance with Good Clinical 
Practice, all applicable subject privacy requirements, and the guiding principles of the declaration of Helsinki. The study   received ethics 
committee approval, reference 12/EM/0413. Consent was gained for the use of patients’ pulmonary function tests to determine disease  
severity. 
Data regarding lung function measured at baseline and 6 and 12 months   preceding recruitment to the study was collected in order to 
classify the IPF patients as having previous stable or declining lung function. Subsequent data regarding mortality and inpatient admissions 
was collected up to   September 2015 using the Sunquest ICE (Integrated Clinical Environment) system at the Norfolk and Norwich University 
Hospital. 
All study subjects were asked to complete a number of questionnaires; these were all self- completed either at home or in the outpatient 
clinic waiting room (unsupervised by a   health professional). Questionnaires were completed in the following   order: 
 
1. Hospital Anxiety and Depression Scale (HADS)  (18) 
2. EuroQoL 5D (EQ5D) (19,20) 
 
26  
3. King’s Brief Interstitial Lung Disease questionnaire (K-BILD)  (21) 
 
4. MRC dyspnoea scale (MRCd) (22) 
 
5. Fatigue Assessment Scale (FAS) (23) 
 
6. St George’s Respiratory Questionnaire (SGRQ) (24,25)  
 
7. Non-validated questionnaire  
For the questionnaires above, higher scores in the EQ5D and K-BILD   questionnaires a less impaired HRQOL, whereas higher scores in the 
SGRQ indicate a more   impaired HRQOL. Higher scores in the HADS, MRCd and FAS questionnaires indicate a higher   degree of anxiety, 
depression, dyspnoea or fatigue respectively. 
Were: “How confident are you about when to call a doctor?”, with the response options on a  5 point scale (1 representing “not at all” and   
5 representing “very confident”) and “Have you discussed with a doctor what you can do  to keep yourself as well as possible?”, with 
response options “yes” or “no”. Use of community healthcare resources was assessed by asking them to report the number of times they 
had sought help from a doctor, nurse or other health professional in the community over the year preceding recruitment to the study for 
pulmonary fibrosis or for other reasons. The questionnaire also asked participants to report the duration of any cough or breathlessness in 
order to assess whether patient confidence was related to duration of   symptoms. 
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Statistical Analysis 
 
Spearman’s rank correlation coefficient was used to assess for any correlation between the following parameters: level of confidence about 
when to call a doctor, age, duration of   cough and breathlessness, number of times a doctor, nurse or other health professional had been 
consulted over the 12 months preceding recruitment to the study, number of emergency inpatient admissions and questionnaire scores 
(HADS-Anxiety (HADS-A), HADS- Depression (HADS-D), MRCd score, total K-BILD score, EQ5D score, total SGRQ  scores, and FAS score). A 
two-tailed t-test was performed to assess whether the mean level of confidence about when to call a doctor differed according to gender. 
 
Two-tailed t-tests were performed to assess whether   questionnaire scores (as above) differed in patients who had discussed with a doctor 
how they could optimise their wellbeing compared to those who had not. The chi-square test was used   to assess for any association 
between level of confidence in when to call a doctor   and discussion of optimisation of wellbeing with a  doctor. 
 
For the IPF cohort chi-square tests were performed to assess for   any difference in level of confidence about when to call a doctor according 
to mortality status, disease severity as measured by lung function at recruitment and previous stable versus declining lung function. 
All statistical analysis was performed using IBM SPSS version  22. 
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Results 
 
144 subjects were recruited to the study: 75 patients with  a diagnosis of IPF and 69 with a diagnosis of sarcoidosis. Of the IPF cohort, lung 
function was obtained for 63 patients at recruitment. Multiple lung function measurements enabling measurement of decline in lung 
function was obtained for 54 of the IPF patients; of these 21 (28%) had declining lung function. The patient characteristics are summarised in 
table   1. 
The questionnaire completion rate was 89% (incomplete questionnaires were not   included in statistical analysis). For the IPF cohort, 
significant negative correlation was found   between level of confidence in when to call a doctor and level of depression, fatigue and number   
of emergency inpatient admissions due to lung disease. Significant positive correlation   was found between level of confidence in when to 
call a doctor and HRQOL as measured by   the EQ5D (Table 2).  
No significant correlation was found   between level of confidence in when to call a doctor and gender, age, duration of cough   or 
breathlessness, MRCd score, HADS-A score, K-BILD score, total SGRQ score, or the number of time   patients sought help from a doctor, nurse 
or other health professional in the community. For the sarcoidosis cohort, no correlation was found between level of confidence   in  
when to call a doctor and any of the parameters tested (Table  3). 
 
When investigating whether subjects had discussed with a doctor how they could optimise their wellbeing, no difference was found in any of 
the parameters tested for the IPF   cohort (Table 4). For the sarcoidosis cohort, participants who had had discussed optimisation   of  
wellbeing with their doctor this had a significantly higher level of depression, dyspnoea and fatigue and  a significantly lower level of quality 
of   life as measured by the scores in all of the questionnaires used (Table 5). The mean level   of confidence in when to call a doctor for help 
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did not differ between subjects who had discussed with a doctor how they could optimise their wellbeing and those who had not   (IPF 
cohort: mean confidence level 3.8 versus 3.7 for those who had discussed versus those   who  had not discussed optimising wellbeing with 
their doctor, p=0.958; sarcoidosis cohort   mean confidence level 4.1 versus 3.6 for those who had discussed versus those who had   not 
 
discussed optimising wellbeing with their doctor,  p=0.053). 
 
Analysis of the IPF cohort revealed no significant difference in the level of confidence in when to call a doctor according to mortality status, 
more   versus less advanced disease or previous stable versus declining lung   function. 
 
Discussion 
 
Patient confidence versus HRQOL 
 
A lower level of confidence in when to call a doctor was associated with   significantly higher scores of depression and, fatigue, and a more 
impaired quality   of life as assessed by the EQ5D in IPF patients. Whilst patients with a higher level of confidence had fewer emergency 
admissions due   to lung disease, there was no association of confidence with disease severity. This emphasizes the importance of obtaining 
patients’ subjective accounts of the effect   of their condition on their lives, in addition to monitoring disease   progression  objectively, as 
objective measures of disease progression may not accurately reflect the   full impact IPF has on patients’ lives. 
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For the sarcoidosis cohort, there was no association between any of the parameters   tested and level of confidence in when to call a doctor. 
The reasons for the difference between   the IPF and sarcoidosis cohorts are unclear, however the demographics of the cohorts   were 
different, with the IPF cohort being older, having a higher proportion of males and a   higher burden of respiratory disease as assessed by the 
SGRQ score, which may in part explain   the difference in results. 
 
Discussion of optimisation of wellbeing 
 
Discussion of optimisation of wellbeing was associated with higher levels of   depression, dyspnoea and fatigue and a more impaired HRQOL 
in the sarcoidosis cohort, however   no association was seen with any of the variables in the IPF cohort. As the questionnaires   were only 
completed at a single point in time, it is unclear what impact the discussion   of optimising wellbeing had on the various questionnaire scores 
(i.e. whether for   example, high levels of depression prompted the discussion, persisted despite the discussion or   arose in spite of it). 
Nevertheless, it would be of value to implement interventions to try   and improve the mood, breathlessness, energy levels and quality of life 
of these patients.   Given that discussion of optimisation of wellbeing with a doctor was not associated with   higher confidence levels, it 
seems that discussions with doctors alone is inadequate to   achieve these aims. 
 
As can be seen from Table 1, a higher proportion of IPF patients had discussed   optimizing wellbeing with their doctor compared to the 
sarcoidosis cohort, however mean   confidence levels were comparable between the two cohorts. The mean age of the IPF cohort   was 
greater than that of the sarcoidosis cohort, which may account for the greater rate   of discussion of optimising wellbeing with their doctor, 
as this older group of patients   may have had more health concerns to address. The fact that such a high proportion of   IPF patients 
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discussed optimising wellbeing with their doctor may have made it more difficult   to detect any differences in the questionnaire values 
between those who did or did not   discuss the topic, which may explain why the results were not statistically  significant. 
 
Our study findings highlight the importance of implementing interventions to improve confidence in patients with ILD, in order to try and 
improve their quality of life. These interventions may take the form of patient self-help groups, counselling, education and support. Wuyts et 
al. (29) have suggested that models for patient-centred care used for palliative patients may be useful in IPF to help address patient 
expectations when there is a poor prognosis. They suggest the utility of the “three pillars of care” model (30), encompassing disease-centred 
management, symptom-centred management and education and self-management. 
A qualitative survey of IPF patients from five European countries (31) has highlighted the  need to provide emotional support for patients 
from the time of their diagnosis, in view of patients reporting feelings of apprehension, confusion and devastation when being  diagnosed 
with IPF. IPF patients have themselves expressed a need for greater healthcare support and education in the form of patient-based advocacy 
groups, familial support and counselling programmes (32). Patients managed at a tertiary care centre who had been    given the opportunity 
to interact with other patients with IPF felt this was beneficial in    terms of gaining psychological support and practical disease management 
tips, in contrast to those who were mainly managed in the community and felt less well-informed about their disease and treatment options 
(32). 
 
Previous studies investigating the effect of interventions to improve education and support for IPF patients have reported positive results 
based on patient satisfaction surveys (11) and post-study qualitative interviews (10). Our study is the first to suggest an   association 
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between low levels of confidence and a low level of quality of life by performing quantitative analysis using a validated measures of   HRQOL. 
Studies of interventions aiming to promote patient empowerment in COPD have shown benefits in terms of increased cost-effectiveness of 
care and fewer visits by primary care physicians in the intervention group compared to the control group (33), as well as patients perceiving 
their condition and its treatment as less intrusive (34). Whilst there are no pre- existing studies assessing the effect of improving patient 
confidence in sarcoidosis and conflicting evidence in IPF, our finding of an association between low levels of confidence and a low level of 
quality of life suggests that it would be worth assessing whether, like in COPD patients, promoting patient confidence will have a beneficial 
effect on sarcoidosis or IPF patients. 
 
Patient confidence versus discussion of wellbeing with a doctor and access to medical services 
Previous discussion of how to improve wellbeing with a doctor did not seem to impact on confidence in when to call a doctor, suggesting 
that there were probably areas that were not addressed adequately during these discussions to improve subjects’ confidence and 
understanding of their condition. Efforts therefore need to be made to try and   adequately address patients’ concerns during such 
discussions to promote their self-efficacy. Given that patients in the IPF Care study reported feeling more comfortable discussing their health    
with a nurse over the telephone than in a clinic environment (11), providing support using a variety of methods in addition to patient 
consultations with doctors may help to maximise patient confidence. 
 
No significant association was found between the level of confidence in when to call a doctor and the number of times medical help was 
actually sought in the community. Whilst it   is reassuring that a lack of confidence in seeking medical help does not translate to less 
utilisation of resources in the community, it is important to consider the effect of low confidence on   patients’ quality of life given the 
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findings of our study. It is unclear whether IPF patients’ lack   of confidence was a result of the greater level of depression, fatigue or worse 
quality of life, or whether it caused or exacerbated these. Helping patients to feel more confident by educating them about their condition 
and encouraging them to be involved with decisions regarding their care may help to improve their quality of life and have a positive impact 
on their level of fatigue and  depression. 
 
Study limitations 
Our study had several limitations. There was recruitment bias in that the   patients approached to take part in the study were those 
attending regular clinic appointments   or support days, or had volunteered to be part of a research database. This led to   an acceptance rate 
of 100% to take part in the study. However we obtained a large   enough sample size that we feel the cohort encompasses individuals who 
have been affected   by their conditions to varying extents and in different  ways. 
 
We did not use a validated tool to assess patient confidence, such as the Self-Efficacy for Managing Chronic Disease 6-Item Scale (35). 
Furthermore, our assessment of patients’ confidence was made by assessing their confidence in when to call a doctor for help about their 
health in general as opposed to specifically for IPF or sarcoidosis-related problems. However regardless of the fact that we did not use a 
validated tool or assess confidence related to patients’ specific condition, we found statistically significant associations between confidence, 
fatigue, depression and quality of  life. 
 
Conclusion 
IPF patients with higher levels of fatigue and depression, and a more impaired quality of life  have a significantly lower level   of confidence in 
34  
when to call a doctor, however this association was not seen in the   sarcoidosis cohort. In sarcoidosis, discussion of optimising wellbeing is 
associated with greater levels   of depression, dyspnoea, fatigue and a more impaired quality of life. Discussing   improving wellbeing with a 
doctor however, did not impact on confidence in either cohort. 
 
For the IPF patients, severity of lung disease and the previous degree of change of lung function were not associated with confidence, 
highlighting the importance of obtaining patients’ subjective accounts of the effect of their condition on their   lives. 
Further studies are required to assess the relationship between patient confidence, disease severity and progression and HRQOL in IPF and 
sarcoidosis patients longitudinally, as well as to assess whether promoting patient confidence has a positive impact on their quality of    life, 
mood and energy levels. 
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Tables 
 
Table 1: Patient demographics and lung  function 
Parameter I
P
F 
S
a
r
c
o
i
d
o
s
i
s 
Number of people(n) 7
5 
6
9 
Age (years) (mean, (S.D.)) 7
6
.
4
 
(
7
.
5
) 
5
9
.
1
 
(
1
3
.
4
) 
Male (n, %) 5
8
 
(
7
7
%
) 
3
5
 
(
5
1
%
) 
Baseline FVC % predicted (mean (S.D.)) 8
3
.
6
 
(
1
9
.
7
) 
9
8
.
5
 
(
2
0
.
4
) 
Baseline TLCO-SB % predicted (mean (S.D)) 5
1
.
0
 
(
1
8
.
9
) 
7
6
.
7
 
(
1
6
.
6
) 
Follow-up in months (mean (S.D)) 2
5
.
2
 
(
1
.
7
) 
2
4
.
2
 
(
3
.
4
) 
More advanced disease (n, %) 1
8
 
(
2
4
%
) 
N
/
A 
Mortality (n, %) 2
3
 
(
3
1
%
) 
2
 
(
3
%
) 
Total SGRQ score (mean, (S.D.)) 4
2
.
8
 
(
2
0
.
4
) 
3
5
.
4
 
(
2
1
.
3
) 
Confidence level in when to call doctor 
(mean, S.D.)) 
3
.
7
 
(
1
.
2
) 
3
.
8
 
(
1
.
1
) 
Discussed optimising wellbeing with 
doctor (n, %) 
4
1
 
(
5
5
%
) 
3
2
 
(
4
6
%
) 
 
Table illustrating demographics, lung function and mean values for selected questionnaires. 
 
Key: n = number of subjects, S.D. = standard deviation, N/A = not applicable (disease severity and decline in lung function only assessed for IPF 
patients) 
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Table 2: Spearman’s rank correlation coefficient analysis results comparing level of confidence in when to call a doctor with scores of HRQOL, 
duration of symptoms, emergency inpatient admissions and access to community healthcare for IPF   cohort 
 
Parameter r
h
o 
p
-
v
a
l
u
e 
Age (years) -
0
.
1
8
7 
0
.
1
1
1 
HADS-A -
0
.
0
7
5 
0
.
5
2
9 
HADS-D -
0
.
2
4
2 
0
.
0
4
1 
MRCd -
0
.
2
1
4 
0
.
0
7
0 
FAS -
0
.
2
7
9 
0
.
0
1
8 
K-BILD 0
.
2
1
5 
0
.
0
7
0 
EQ5D 0
.
2
5
9 
0
.
0
2
7 
SGRQ -
0
.
2
4
4 
0
.
0
5
6 
Duration of cough (months) -
0
.
0
6
0 
0
.
6
3
2 
Duration of breathlessness (months) -
0
.
0
5
9 
0
.
6
5
3 
Total emergency inpatient admissions -
0
.
1
3
3 
0
.
2
5
8 
Emergency inpatient admissions (lung 
disease) 
-
0
.
2
6
1 
0
.
0
2
4 
Times consulted doctor (community) 0
.
0
3
2 
0
.
7
9
3 
Times consulted nurse (community) -
0
.
0
6
0 
0
.
6
3
2 
Times consulted other health professional 
(community) 
-
0
.
0
0
8 
0
.
9
4
9 
 
 Table illustrating Spearman’s rank correlation coefficient analysis results comparing level of confidence in when to call a doctor with various 
parameters for the IPF cohort. Level of confidence in when to call a doctor is significantly positively correlated with the EQ5D scores, and 
significantly negatively correlated with HADS-DA and FAS scores and emergency inpatient admissions due to lung  disease. 
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Table 3: Spearman’s rank correlation coefficient analysis results comparing level of confidence in when to call a doctor with scores of HRQOL, 
duration of symptoms,   emergency inpatient admissions and access to community healthcare for sarcoidosis   cohort 
 
 
Parameter r
h
o 
p
-
v
a
l
u
e 
Age (years) 0
.
0
3
5 
0
.
7
8
4 
HADS-A -
0
.
0
2
0 
0
.
8
7
4 
HADS-D -
0
.
0
4
0 
0
.
7
5
3 
MRCd 0
.
1
4
9 
0
.
2
5
5 
FAS -
0
.
1
3
8 
0
.
2
8
0 
K-BILD 0
.
0
2
0 
0
.
8
7
8 
EQ5D -
0
.
1
0
4 
0
.
4
3
5 
SGRQ 0
.
0
1
6 
0
.
9
0
8 
Duration of cough (months) -
0
.
1
4
2 
0
.
2
9
7 
Duration of breathlessness (months) -
0
.
0
5
9 
0
.
6
7
8 
Total emergency inpatient admissions 0
.
1
0
2 
0
.
4
2
6 
Emergency inpatient admissions (lung 
disease) 
0
.
1
8
3 
0
.
1
5
1 
Times consulted doctor (community) 0
.
0
8
7 
0
.
5
1
4 
Times consulted nurse (community) 0
.
0
6
7 
0
.
6
1
3 
Times consulted other health professional 
(community) 
0
.
1
2
1 
0
.
3
6
9 
 
 Table illustrating Spearman’s rank correlation coefficient analysis results comparing level of confidence in when to call a doctor with various 
parameters for the sarcoidosis cohort. No correlation was found between any of the  variables. 
45  
Table 4: Two-tailed t-test analysis results comparing patients who had discussed optimising their wellbeing with a doctor with those who had 
not (IPF  cohort). 
 
 
Parameter 
D
i
s
c
u
s
s
e
d
 
(
m
e
a
n
, 
(
S
.
D
.
)
N
o
t 
d
is
c
u
s
s
e
d 
(
m
e
a
n
, 
(
S
.
D
.)
 
p
-
v
a
l
u
e 
HADS-A 5
.
7
 
(
3
.
7
) 
5
.
6 
(
4
.
1
) 
0
.
9
2
3 
HADS-D 5
.
1
 
(
3
.
8
) 
4
.
6 
(
3
.
9
) 
0
.
6
2
2 
MRCd 2
.
9
 
(
1
.
1
) 
2
.
5 
(
1
.
1
) 
0
.
1
4
3 
AS 2
4
.
4
 
(
7
.
3
) 
2
2
.
0 
(
7
.
0
) 
0
.
1
8
2 
K-BILD 6
9
.
3
 
(
1
9
.
1
) 
7
4
.
9 
(
1
9
.
6
) 
0
.
2
2
8 
EQ5D 6
0
.
0
 
(
2
2
.
1
) 
6
5
.
4 
(
2
2
.
3
) 
0
.
3
1
2 
SGRQ 4
2
.
6
 
(
1
9
.
8
) 
4
3
.
7 
(
2
0
.
0
) 
0
.
8
3
7 
 
Table illustrating two-tailed t-test analysis results comparing patients who had discussed optimising their wellbeing with a doctor with those 
who had not (IPF cohort). There was no  difference in any of the parameters according to whether patients had discussed optimising wellbeing 
with their doctor. 
 
Key: S.D. = standard deviation, CI = confidence  interval 
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Table 5: Two-tailed t-test analysis results comparing patients who had discussed optimising their wellbeing with a doctor with those who had 
not (sarcoidosis cohort) 
 
 
Parameter 
D
i
s
c
u
s
s
e
d
 
(
m
e
a
n
, 
(
S
.
D
.
)
N
o
t 
d
is
c
u
s
s
e
d 
(
m
e
a
n
, 
(
S
.
D
.)
 
p
-
v
a
l
u
e 
HADS-A 7
.
5
 
(
4
.
0
) 
5
.
8 
(
3
.
8
) 
0
.
0
8
6 
HADS-D 6
.
3
 
(
4
.
1
) 
4
.
1 
(
3
.
7
) 
0
.
0
2
8 
MRCd 2
.
7
 
(
1
.
2
) 
2
.
0 
(
0
.
8
) 
0
.
0
0
8 
FAS 2
7
.
4
 
(
9
.
3
) 
2
2
.
9 
(
8
.
1
) 
0
.
0
3
9 
K-BILD 7
3
.
8
 
(
2
0
.
1
) 
8
4
.
8 
(
1
2
.
7
) 
0
.
0
1
4 
EQ5D 6
0
.
0
 
(
1
9
.
8
) 
7
1
.
6 
(
1
9
.
3
) 
0
.
0
2
5 
SGRQ 4
2
.
1
 
(
2
3
.
1
) 
2
9
.
8 
(
1
7
.
8
) 
0
.
0
2
6 
 
 
Table illustrating two-tailed t-test analysis results comparing patients who had discussed optimising their wellbeing with a doctor with those 
who had not (sarcoidosis   cohort). 
Patients who had discussed optimising their wellbeing with their doctor had significantly higher scores on the HADS-D, MRCd, FAS and SGRQ 
and significantly lower scores on the K- BILD and EQ5D. 
 
Key: S.D. = standard deviation, CI = confidence  interval 
